Citadel Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.65M | Sell |
1,314,552
-1,341,159
| -51% | -$6.79M | ﹤0.01% | 1671 |
|
|
2025
Q1 | $14M | Sell |
2,655,711
-83,536
| -3% | -$442K | ﹤0.01% | 1063 |
|
|
2024
Q4 | $18.5M | Buy |
2,739,247
+2,505,024
| +1,070% | +$16.9M | ﹤0.01% | 969 |
|
|
2024
Q3 | $1.54M | Sell |
234,223
-510,856
| -69% | -$3.37M | ﹤0.01% | 2724 |
|
|
2024
Q2 | $5.59M | Buy |
745,079
+404,705
| +119% | +$3.04M | ﹤0.01% | 1604 |
|
|
2024
Q1 | $3.39M | Buy |
340,374
+303,880
| +833% | +$3.03M | ﹤0.01% | 2053 |
|
|
2023
Q4 | $360K | Sell |
36,494
-266,596
| -88% | -$2.63M | ﹤0.01% | 4058 |
|
|
2023
Q3 | $2.32M | Sell |
303,090
-434,668
| -59% | -$3.33M | ﹤0.01% | 2270 |
|
|
2023
Q2 | $5.51M | Buy |
737,758
+132,243
| +22% | +$988K | ﹤0.01% | 1647 |
|
|
2023
Q1 | $4.04M | Sell |
605,515
-165,635
| -21% | -$1.1M | ﹤0.01% | 1977 |
|
|
2022
Q4 | $5.95M | Buy |
771,150
+269,280
| +54% | +$2.08M | ﹤0.01% | 1649 |
|
|
2022
Q3 | $5.34M | Buy |
501,870
+194,498
| +63% | +$2.07M | ﹤0.01% | 1794 |
|
|
2022
Q2 | $2.5M | Sell |
307,372
-602,598
| -66% | -$4.91M | ﹤0.01% | 2523 |
|
|
2022
Q1 | $6.52M | Buy |
909,970
+710,363
| +356% | +$5.09M | ﹤0.01% | 1826 |
|
|
2021
Q4 | $3.42M | Buy |
+199,607
| New | +$3.42M | ﹤0.01% | 2490 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 6984 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 6994 |
|